Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lovastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 2/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | ITGAL | P20701 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lovastatin SCHEMBL13415684 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL14307240 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL3136 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340570 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23468171 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL12137502 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23636214 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340553 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340569 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340572 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 100747 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144789-A1 | WOUND TREATMENTS AND COMPOSITIONS | CMPD LICENSING, LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4507690-B1 | COMBINATION OF DASATINIB AND LOVASTATIN FOR USE IN METHODS FOR THE TREATMENT OF CARDIAC FIBROSIS | INST NAT SANTE RECH MED (FR) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075699-A | Application of calcium activated chloride channel AN01/TMEM16A in preventing and treating atherosclerosis | — | 2026-05-26 | — | — | CN | claimed |
| US-12640239-B2 | Functional biomarkers for statin therapy in age-related macular degeneration (AMD) | APELIOTUS TECHNOLOGIES, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-12636273-B2 | Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders | YALE UNIVERSITY (US) | 2026-05-26 | — | — | US | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122038089-A | Method for improving flavor and nutritional functional components of solid brewing vinegar by using monascus purpureus-eurotium cristatum and weeping forsythia tea yeast | 晋中市综合检验检测中心 | 2026-05-15 | — | — | CN | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| US-4946686-A | Solubility modulated drug delivery system | MERCK & CO., INC. (US) | 1990-08-07 | — | — | US | claimed |
| EP-0373507-A1 | Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-06-20 | — | — | EP | claimed |
| US-4933165-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-06-12 | — | — | US | claimed |
| US-4929437-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-05-29 | — | — | US | claimed |
| US-4920111-A | SYNERGISTIC | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | claimed |
| US-4920109-A | COADMINISTERING A 25-AZASTEROL WITH A NON-STEROIDAL AGENT; NONTOXIC, SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |
| EP-0339709-A2 | Antifungal compositions and method of controlling mycotic infections | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0339708-A2 | Fungicidal compositions and method | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0302693-A2 | Device for the controlled release of drugs with donnanlike modulation by charged insoluble resins | MERCK & CO. INC. (US) | 1989-02-08 | — | — | EP | claimed |